Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, Aug. 20, 2026 SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the...
PR Newswire
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Atrium Therapeutics Reports Second Quarter 2026 Financial Results Atrium Therapeutics Reports Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, Aug. 13, 2026 -- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome ---- Achieved second milestone payment...
PR Newswire
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration PR Newswire SAN DIEGO, Aug. 13, 2026 SAN DIEGO...
PR Newswire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, July 20, 2026 SAN DIEGO, July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the...
PR Newswire
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome PR Newswire SAN DIEGO, July 14, 2026...
PR Newswire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, June 23, 2026 SAN DIEGO, June 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the...
PR Newswire
Atrium Therapeutics Reports First Quarter 2026 Financial Results
Atrium Therapeutics Reports First Quarter 2026 Financial Results Atrium Therapeutics Reports First Quarter 2026 Financial Results PR Newswire SAN DIEGO, May 14, 2026 SAN DIEGO, May 14, 2026...
PR Newswire
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers...
PR Newswire
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, April...
PR Newswire
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies Atrium Therapeutics Launches with Approximately $270 Million to Advance...
PR Newswire